Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints. www.marketwatch.com #Sareptas #stock #plummets #disappointing #trial…
